The Covid-19 vaccine ‘BNT162b1’, developed by the biotechnology company BioNTech, has begun to be tested on humans in China, after the USA and Germany. According to the data of the World Health Organization, 27 vaccines are still in clinical trials.

Turkish scientist Prof. Dr. The new type of coronavirus vaccine candidate developed by the biotechnology company “BioNTech”, of which Uğur Şahin is the founding partner, has begun to be tested on people in China.

According to the news on the “Clinical Trials Arena” website, Fosun Pharma pharmaceutical company, headquartered in Shanghai, is conducting the first stage clinical trials of the vaccine candidate “BNT162b1”.

In the trial where the vaccine candidate’s safety and immunity effect was tested, 72 subjects received the first dose of vaccines.

In the trial, which is aimed to involve 144 healthy volunteers aged 18 to 55 and over 55, subjects will be given two doses of 10 and 30 micrograms of vaccine at 21 days apart.

The vaccine called BNT162b1 was previously tested on humans in the USA and Germany.

THE VACCINE IS INTENDED TO TEST 30 THOUSAND HEALTHY VOLUNTEERS

The RNA-based vaccine aims to activate uptake-binding Immunoglobulin G antibodies with blood glucose enzymes that inactivate Covid-19, and increase CD4 + and CD8 + glycoproteins that create an immune response at the cell level.

The production rights of the vaccine candidate have been acquired by the pharmaceutical companies Pfizer in the USA and Fosun Pharma in China.

The third stage clinical trials of the vaccine, which had positive results from first and second stage clinical trials in Germany and the USA, started with human tests in the USA on July 27.

It is among the targets to test the vaccine candidate on 30 thousand healthy volunteers worldwide.

SECOND STAGE IN CLINICAL TRIALS OF INDIAN DOMESTIC PRODUCTION VACCINE

On the other hand, it was announced that the second stage in the clinical trials of the domestic production vaccine candidate named “ZyCoV-D” developed by Zydus Cadila pharmaceutical company in India.

See Also
China strengthens its superiority in quantum communication

In the statement made by the company, it was reported that the vaccine candidate was safe in the first stage clinical trials, and positive results were obtained in terms of immune effect and body tolerance in the subjects.

In the second stage, it was announced that the vaccine candidate will be tested on 1000 healthy volunteers.

It was stated that the potential vaccine developed by the company in the Vaccine Technology Center in Ahmedabad, “managed to evoke strong immune responses” in experiments on animals, in different species.

The Indian General Drug Inspectorate (DCGI) approved the vaccine candidate to be tested in humans on July 3.

In addition to Zydus Cadila in India, Bharat Biotech pharmaceutical company is also working to develop a local vaccine. Phase 1 clinical trials of the Covid-19 vaccine candidate named “Covaxin”, developed by the company in collaboration with the Indian Medical Research Council and the National Virology Institute, started on July 25.

27 VACCINE CANDIDATES AT CLINICAL TRIAL

According to the data of the World Health Organization (WHO), 27 Covid-19 vaccine candidates are being tested on humans in clinical trials worldwide as of July 31. 139 vaccine candidates are in pre-clinical development.

CLINICAL TRIALS ARE MADE IN 3 STAGES

In order for a vaccine to be widely used, it must be tested on humans in 3 stages.

In the first phase of clinical trials, the safety of the vaccine and possible side effects are tested on a small number of healthy volunteers.

The effectiveness of the vaccine, whose reliability was confirmed in the second stage, is tested on more than 100 subjects.

In the third and last stage, the same process is repeated once more with thousands of subjects.

This whole process can take months or even years.

LEAVE A REPLY

Please enter your comment!
Please enter your name here